Loading...
XSTO
ONCO
Market cap33mUSD
Jun 10, Last price  
1.51SEK
1D
-0.66%
1Q
-6.21%
IPO
-96.40%
Name

Oncopeptides AB

Chart & Performance

D1W1MN
P/E
—
P/S
10.08
EPS
—
Div Yield, %
—
Shrs. gr., 5y
26.34%
Rev. gr., 5y
0.00%
Revenues
32m
-10.14%
0000000118,295,0008,355,00035,220,00031,648,000
Net income
-285m
L+14.25%
-33,093,978-53,341,000-114,445,869-247,620,000-419,449,000-740,705,000-1,594,693,000-1,430,318,000-337,951,000-249,111,000-284,607,000
CFO
-261m
L-6.77%
-31,438,604-52,808,000-104,262,104-271,497,000-333,727,000-690,566,000-1,296,509,000-1,516,391,000-420,509,000-279,493,000-260,570,000
Earnings
Aug 21, 2025

Profile

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
URL
https://www.oncopeptides.se/
IPO date
Feb 22, 2017
Employees
63
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
31,648
-10.14%
35,220
321.54%
8,355
-92.94%
Cost of revenue
321,131
294,348
359,858
Unusual Expense (Income)
NOPBT
(289,483)
(259,128)
(351,503)
NOPBT Margin
Operating Taxes
398
664
271
Tax Rate
NOPAT
(289,881)
(259,792)
(351,774)
Net income
(284,607)
14.25%
(249,111)
-26.29%
(337,951)
-76.37%
Dividends
Dividend yield
Proceeds from repurchase of equity
(24)
407,944
BB yield
0.00%
-40.79%
Debt
Debt current
5,999
Long-term debt
121,894
145,825
13,085
Deferred revenue
Other long-term liabilities
16,658
10,509
1,815
Net debt
(56,642)
(27,614)
(326,282)
Cash flow
Cash from operating activities
(260,570)
(279,493)
(420,509)
CAPEX
(116)
(2,507)
Cash from investing activities
496
(116)
(2,507)
Cash from financing activities
263,814
106,889
392,402
FCF
(282,366)
(273,980)
(347,468)
Balance
Cash
178,536
173,439
344,515
Long term investments
851
Excess cash
176,954
171,678
344,948
Stockholders' equity
(5,355,476)
(5,105,935)
Invested Capital
192,837
5,548,921
5,404,807
ROIC
ROCE
EV
Common stock shares outstanding
166,437
126,836
82,320
Price
1.56
-79.63%
7.66
-36.95%
12.15
44.64%
Market cap
259,641
-73.28%
971,561
-2.86%
1,000,188
58.14%
EV
202,999
943,947
676,203
EBITDA
(289,483)
(248,088)
(334,342)
EV/EBITDA
Interest
5,785
883
Interest/NOPBT